MedTrace Logo

The Effect of PPI in Preventing Gastroesophageal Reflux Disease of Seafarers

NCT04696783 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2021-01-06

No results posted yet for this study

Summary

In view of the high incidence of GERD among seafarers and its continuing impact on the life quality of seafarers, it is necessary to use preventive treatment. At the same time, because both mental and psychological factors and changes in intestinal flora may play a certain role in the development and treatment of GERD, this project intends to take the seafarers involved in this scientific expedition as the participants to explore the effect of PPI discontinuous therapy in preventing gastroesophageal reflux disease of seafarers, a special occupational group and the changes in the mental and psychological status and intestinal flora of this group of people after PPI therapy.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Esomeprazole Magnesium Enteric-coated Tablets

Nexium taken once every 2 days plus lifestyle adjustment

BEHAVIORAL

Lifestyle adjustment

Lifestyle adjustment

Sponsors & Collaborators

  • Fifth Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Hong Shan, MD · Fifth Affiliated Hospital of Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2021-09-30
Completion
2021-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04696783 on ClinicalTrials.gov